Abiomed Stock News

Here is how Abiomed (ABMD) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 40th annual J.P. Morgan Healthcare Conference.

Banque Cantonale Vaudoise cut its stake in shares of Abiomed, Inc. (NASDAQ:ABMD) by 12.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,000 shares of the medical equipment provider’s stock after selling 140 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Abiomed were worth $326,000 as of its most recent filing […]

Wall Street analysts forecast that Abiomed, Inc. (NASDAQ:ABMD) will announce earnings of $0.98 per share for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Abiomeds earnings. The highest EPS estimate is $1.04 and the lowest is $0.87. Abiomed reported earnings per share of $1.17 during the same quarter last []

Park Avenue Securities LLC acquired a new position in Abiomed, Inc. (NASDAQ:ABMD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 624 shares of the medical equipment providers stock, valued at approximately $203,000. Other large investors have also modified their []

PAX Financial Group LLC lifted its holdings in Abiomed, Inc. (NASDAQ:ABMD) by 26.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,441 shares of the medical equipment providers stock after purchasing an additional 507 shares during the quarter. PAX Financial Group LLCs holdings in Abiomed were worth $795,000 as of its most recent filing []

Investors may want to consider the following stocks, since they are growing earnings faster than sales, which may indicate efficient operating activities as profit margins expand along with growth.

Congestive Heart Failure (CHF) may be a state that has associate adverse impact on the pumping potency of the internal organ muscles. It characterizes the buildup of fluid round the heart resulting in inefficient pumping. Congestive Heart Failure (CHF) Treatment Devices

Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.

Exchange Traded Concepts LLC reduced its position in Abiomed, Inc. (NASDAQ:ABMD) by 22.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,505 shares of the medical equipment providers stock after selling 2,985 shares during the quarter. Exchange Traded []

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- Technavio''s latest offering, the Ventricular Assist Devices Market report provides a detailed analysis of the competitive scenario and the market growth across various regions. The ventricular assist devices market value is set to grow by USD 4.05

State of Alaska Department of Revenue lowered its position in Abiomed, Inc. (NASDAQ:ABMD) by 0.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,219 shares of the medical equipment providers stock after selling 167 shares during the period. State of []

Abiomed (NASDAQ:ABMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. The firm presently has a $369.00 target price on the medical equipment provider’s stock. Zacks Investment Research‘s price target indicates a potential upside of 7.42% from the company’s previous close. According […]

Abiomed, Inc. (NASDAQ:ABMD) has earned an average recommendation of Hold from the six analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among []